In melanoma and colon syngeneic mouse models, ALKBH5 attenuates tumor response to anti-PD-1 therapy by modulating Mct4/Slc16a3 expression, lactate content, as well as the composition of myeloid-derived suppressor cells and tumor-infiltrating Treg cells in the tumor microenvironment [46]. This evidence concerns the gene PDCD1 and neoplasm.